Previous close | 0.6998 |
Open | 0.7007 |
Bid | 0.6475 x 400 |
Ask | 0.6601 x 400 |
Day's range | 0.6500 - 0.7110 |
52-week range | 0.1990 - 2.5350 |
Volume | |
Avg. volume | 1,656,440 |
Market cap | 78.27M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Biogen's (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latter's lead asset, felzartamab.
GSK's depemokimab has the potential to become the first ultra-long-acting biologic for severe asthma with a six-month dosing schedule
Atara Biotherapeutics ( NASDAQ:ATRA ) First Quarter 2024 Results Key Financial Results Revenue: US$27.4m (up by...